Likewise, ACT therapies, including TILs, CAR-T cells, and CAR-NK cells, have shown encouraging activity in targeting lung cancer-associated antigens such as EGFR, MUC1, and mesothelin (99–102). This evidence concerns the gene EGFR and lung cancer.